Información del artículo
Los marcadores bioquímicos de remodelado óseo son sustancias liberadas a la circulación durante la formación y resorción ósea que reflejan la actividad metabólica del hueso en un momento puntual. Pueden ser determinados en sangre y en orina.
Se clasifican en marcadores de formación ósea y marcadores de resorción ósea.
Su determinación puede ser de utilidad en la investigación clínica y básica de las enfermedades metabólicas del hueso.
Aunque algunos de estos marcadores tienen capacidad para predecir el riesgo de fracturas, no permiten cuantificar la masa ósea.
En el momento actual, la amplia variabilidad en la sensibilidad y especificidad de los marcadores disponibles cuestiona su utilidad en la práctica clínica.
Biochemical markers of bone turnover are products released to circulation during bone formation or bone resorption, and they reflect the bone metabolic activity at a certain moment.
We can measured them in serum or in orine and they are usually classified, according to the metabolic process they are considered to reflect, in: markers of bone formation or markers of bone resorption.
Their measurement can be useful in clinical research and routine clinical practice in metabolic bone diseases. Although some of these markers are able to predict risk fracture, they can't quantify bone mass.
At the present time, the use of these markers in the routine clinical practice is questionable because of the wide variability in sensibility and specifity
Key words:
Bone markers
Bone formation
Bone resorption
Fracture
Bone mineral density
Palabras clave:
Marcadores de remodelado óseo
Formación ósea
Resorción ósea
Fractura
Densidad mineral ósea
El Texto completo está disponible en PDF
Bibliografía
[1.]
M.S. Calvo, D.R. Eyre, C.M. Gundberg.
Molecular basis and clinical application of biological markers of bone turnover.
Endocr Rev, 17 (1996), pp. 333-368
[2.]
G.J. Strewler.
Bone anatomy and remodeling.
Basic and clinical endocrinology, pp. 290-295
[3.]
E.F. Eriksen.
Normal and pathological remodeling of human trabecular bone: three dimensional reconstruction of the remodelling sequence in normals and in metabolic bone disease.
Endocr Rev, 7 (1986), pp. 379-410
[4.]
P.D. Delmas, P. Garnero.
Utility of biochemical markers of bone turnover in osteoporosis.
Osteoporosis, pp. 1075-1088
[5.]
P.D. Delmas.
Biochemical markers of bone turnover for the clinical assessment of metabolic bone disease.
Endocrinol Metab Clin North Am, 19 (1990), pp. 1-18
[6.]
C.S. Hill, R.L. Wolfert.
The preparation of monoclonal antibodies which react preferentially with human bone alkaline phosphatase and not liver alkaline phosphatase.
Clin Chim Acta, 186 (1989), pp. 315-320
[7.]
R. Eastell, P.D. Delmas, S.F. Hodgson, E.F. Eriksen, K.G. Mann, B.L. Riggs.
Bone formation rate in older normal women: concurrent assessment with bone histomorphometry, calcium kinetics, and bochemical markers.
J Clin Endocrinol Metab, 67 (1988), pp. 741-748
[8.]
P.A. Price, M.K. Williamson, J.W. Lothringer.
Origin of vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone.
J Biol Chem, 256 (1981), pp. 12760-12766
[9.]
P. Charles, J.W. Poser, L. Mosekilde, F.T. Jensen.
Estimation of bone turnover evaluated by 47Ca-kinetics.
J Clin Invest, 76 (1985), pp. 2254-2258
[10.]
J. Brown, L. Malaval, M. Chapuy, P. Delmas, C. Edouard, P. Meunier.
Serum bone GLA-protein: a specific marker for bone formation in postmenopausal osteoporosis.
Lancet, 19 (1984), pp. 1091-1093
[11.]
P.J. Marie, A. Sabbagh, M.C. de Vernejoul, A. Lomri.
Osteocalcin and deoxyribonucleic acid synthesis in vitro and histomorphometric indices of bone formation in postmenopausal osteoporosis.
J Clin Endocrinol Metab, 69 (1989), pp. 272-279
[12.]
P. Vergnaud, P. Garnero, P.J. Meunier, G. Bréart, K. Kamihagi, P.D. Delmás.
Undercarboxylted osteocalcin measured with an specific inmunoassay predicts hip fracture in elderly women: The EPIDOS study.
J Clin Endocrinol Metab, 82 (1997), pp. 719-724
[13.]
J. Melkko, S. Niemi, J. Risteli.
Radioinmunoassay of the carboxyterminal propeptide of human type I procollagen.
Clin Chem, 36 (1990), pp. 1328-1332
[14.]
P.R. Ebeling, J.M. Peterson, B.L. Riggs.
Utility of type procollagen propeptide assays for assesing abnormalities in metabolic bone diseases.
J Bone Miner Res, 7 (1992), pp. 1243-1250
[15.]
R. Eastell, S.P. Robins, T. Colwell, A.M.A. Assiri, B.L. Riggs, R.G.G. Rusell.
Evaluation of bone turnover in type I osteoporosis using biochemical markers specific for both bone formation and bone resorption.
Osteopor Int, 3 (1993), pp. 255-260
[16.]
J. Bollerslev, S.C. Marks Jr, S. Pockwinse, M. Kassem, K. Brixen, T. Steiniche, et al.
Ultrastructural investigations of bone resorptive cells in two types of autosomal dominant osteopetrosis.
Bone, 14 (1993), pp. 865-869
[17.]
S.P. Robins, A. Duncan, B.L. Riggs.
Direct measurement of free hydroxypriridinium crosslinks of collagen in urine as new markers of bone resorption in osteoporosis.
Osteoporosis, pp. 465-468
[18.]
D. Eyre.
New biomarkers of bone resorption [editorial].
J Clin Endocrinol Metab, 74 (1992), pp. A470-A471
[19.]
D.R. Eyre, T.J. Koob, K.P. Van Ness.
Quantitation of hydroxypyridinium crosslinks in collagen by high-performance liquid chromatography.
An Biochem, 137 (1984), pp. 380-388
[20.]
R. Eastell, L. Hampton, A. Colwell.
Urinary collagen crosslinks are highly correlated with radio isotopic measurements of bone resorption.
Proceedings of the third International Symposium on Osteoporosis, pp. 469-470
[21.]
D. Uebelhart, E.C. Gineyts, M.C. Chapuy, P.D. Delmas.
Urinary excretion of pyridinium cross-links: a new marker of bone resorption in metabolic bone disease.
Bone Miner, 8 (1990), pp. 87-96
[22.]
A.K. Taylor, S.A. Lueken, C. Libanati, D.J. Baylink.
Biochemical markers of bone turnover for the clinical assessment of bone metabolism.
Rheum Dis Clin North Am, 20 (1994), pp. 589-607
[23.]
C. De la Piedra, M.A. Díaz Martín, E.M. Díaz Diego, A. Rapado.
Correlación entre el telopéptido carboxiterminal del colágeno tipo I y la densidad mineral ósea medida por DEXA en la osteoporosis postmenopáusica.
REEMO, 1 (1992), pp. 30
[24.]
E. Jódar, M. Muñoz-Torres, M. Quesada, J.D. Luna, N. Olea, F. Escobar-Jiménez.
Nuevos marcadores de metabolismo mineral en pacientes hipertiroideos: ¿son realmente útiles?.
REEMO, 4 (1995), pp. 18
[25.]
P. Garnero, E. Gineyts, P. Arbault, C. Christiansen, P.D. Delmas.
Different effects of bisphosphonate and estrogen therapy on free and peptide-bound bone cross-links excretion.
J Bone Miner Res, 10 (1995), pp. 641-649
[26.]
P.D. Miller, D.T. Baran, J.P. Bilezikian, S.L. Greenspan, R. Lindsay, B.L. Riggs, et al.
Practical clinical application of biochemical markers of bone turnover.
J Clin Densitometry, (1999), pp. 2323-2342
[27.]
P. Bettica, A.K. Taylor, J. Talbot, L. Moro, R. Talamini, D.J. Baylink.
Clinical performances of galactosyl hydroxylysine, pyridinoline, and deoxypyridinoline in postmenopausal osteoporosis.
J Clin Endocrinol Metab, 81 (1996), pp. 542-546
[28.]
M.J. Seibel, H. Woitge, C. Scheidt-Nave, G. Leydig-Bruckner, A. Duncan, P. Nicol, et al.
Urinary hydroxypyridinium crosslinks of collagen in population-based screening for overt vertebral osteoporosis: results of a pilot study.
J Bone Miner Res, 9 (1994), pp. 1433-1440
[29.]
D.L. Schneider, E.L. Barrett-Connor.
Urinary N-telopeptide levels discriminate normal, osteopenic, and osteoporotic bone mineral density.
Arch Intern Med, 157 (1997), pp. 1241-1245
[30.]
A.M. McLaren, L.D. Hordon, H.A. Bird, S.P. Robins.
Urinary excretion of pyridinium crosslinks of collagen in patients with osteoporosis and the effects of bone fracture.
Ann Rheum Dis, 51 (1992), pp. 648-651
[31.]
F. Cosman, J. Nieves, C. Wilkinson, D. Schnering, V. Shen, R. Lindsay.
Bone density change and biochemical indices of skeletal turnover.
Calcif Tissue Int, 58 (1996), pp. 236-243
[32.]
M. Bonde, P. Qvist, C. Fledelius, B.J. Riis, C. Christiansen.
Applications of an enzyme immunoassay for a new marker of bone resorption (crosslaps): Follow-up on hormone replacement therapy and osteoporosis risk assessment.
J Clin Endocrinol Metab, 80 (1995), pp. 864-868
[33.]
I.I.I. Chesnut CH, N.H. Bell, G.S. Clark, B.L. Drinkwater, S.C. English, C.C. Johnson Jr, et al.
Hormone replacement therapy in postmenopausal women: Urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.
Am J Med, 102 (1997), pp. 29-37
[34.]
P.D. Ross, W. Knowlton.
Rapid bone loss is associated with increased levels of biochemical markers.
J Bone Miner Res, 13 (1998), pp. 297-302
[35.]
P.L.A. Van Daele, M.J. Seibel, H. Burger, A. Hofman, D.E. Grobbee, J.P. van Leeuwen, et al.
Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam Study.
BMJ, 312 (1996), pp. 482-483
[36.]
P. Garnero, E. Hausherr, M.C. Chapuy, C. Marcelli, H. Grandjean, C. Muller, et al.
Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study.
J Bone Miner Res, 11 (1996), pp. 1531-1538
[37.]
C.H.I. Chesnut, N.H. Bell, G.S. Clark, B.L. Drinkwater, S.C. English, C.C. Johnston, et al.
Hormone replacement therapy in postmenopausal women: urinary N-telopeptide of type I collagen monitors therapeutic effect and predicts response of bone mineral density.
Am J Med, 102 (1997), pp. 29-37
[38.]
J.S. Johansen, B.J. Riis, P.D. Delmas, C. Christiansen.
Plasma BGP: an indicator of spontaneous bone loss and of the effect of oestrogen treatment in postmenopausal women.
Eur J Clin Invest, 18 (1988), pp. 191-195
[39.]
P. Garnero, W.J. Shih, E. Gineyts, D.B. Karpf, P.D. Delmas.
Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment.
J Clin Endocrinol Metab, 79 (1994), pp. 1693-1700
[40.]
GE-H Fuleihan, E.M. Brown, K. Curtis, M.J. Berger, B.M. Berger, R. Gleason, et al.
Effect of sequential and daily continuous hormone replacement therapy on indexes of mineral metabolism.
Arch Intern Med, 152 (1992), pp. 1904-1909
[41.]
B.L. Riggs, L.J. Melton 3rd, W.M. Ofallon.
Drug therapy for vertebral fractures in osteoporosis: evidence that decreases in bone turnover increases in bone mass both determine antifracture efficacy [review].
Bone, 18 (1996), pp. S197-S201
[42.]
D.S. Ross.
Hyperthyroidism, thyroid hormone therapy, and bone.
Thyroid, 4 (1994), pp. 319-326
[43.]
E. Jódar Gimeno, M. Muñoz Torres, F. Escobar Jiménez, M. Quesada Charneco, J.D. Luna del Castillo, N. Olea.
Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover.
Calcif Tissue Int, 61 (1997), pp. 370-376
[44.]
E. Jodar, M. Muñoz-Torres, F. Escobar-Jiménez, M. Quesada, J.D. Luna, N. Olea.
Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism.
J Clin Endocrinol Metab, 82 (1997), pp. 1989-1994
[45.]
L.J. Deftos.
Markers of bone turnover in primary hyperparathyroidism.
The parathyroids, pp. 485-492
[46.]
J.C. Krakauer, M.J. McKenna, N.F. Buderer, D.S. Rao, F.W. Whitehouse, A.M. Parfitt.
Bone loss and bone turnover in diabetes.
Diabetes, 44 (1995), pp. 775-782
[47.]
J.M. Olmos, J.L. Pérez-Castrillón, M.T. García, J.C. Garrido, J.A. Amado, J. González Macías.
Bone densitometry and biochemical bone remodelling markers in type 1 diabetes mellitus.
Bone Miner, 26 (1994), pp. 1-8
[48.]
M. Muñoz-Torres, J. Díaz Pérez de la Madrid, F. Escobar-Jiménez.
Osteocalcin levels in type 1 (insulin-dependent) diabetes mellitus.
Br J Rheumatol, 29 (1990),
[49.]
M. Pedrazzoni, G. Ciotti, G. Pioli, G. Girasole, L. Davoli, E. Palummeri, et al.
Osteocalcin levels in diabetic subjects.
Calcif Tissue Int, 45 (1989), pp. 331-336
[50.]
M. Muñoz-Torres, E. Jódar, F. Escobar-Jiménez, P. López-Ibarra, J.D. Luna.
Bone mineral density measured by dual X-ray absorptiometry in Spanish patients with insulin-dependent diabetes mellitus.
Calcif Tissue Int, 58 (1996), pp. 316-319
[51.]
P.L. Selby, P.A. Shearing, S.M. Marshall.
Hydroxyproline excretion is increased in diabetes mellitus and related to the presence of microalbuminuria.
Diabet Med, 12 (1995), pp. 240-243
[52.]
P.V. Carroll, E.R. Christ, B.A. Bengtsson, L. Carlsson, J.S. Christiansen, D. Clemmons, et al.
Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review.
J Clin Endocrinol Metab, 83 (1998), pp. 382-395
[53.]
E. Torres-Vela, J. Peñafiel, M. Muñoz-Torres, V. Luna, P. Mezquita, F. Escobar-Jiménez.
Evolución de la mása ósea en adultos con deficiencia de hormona de crecimiento en tratamiento sustitutivo.
REEMO, 7 (1998), pp. 34
[53.]
H.K. Nielsen, K. Thomsen, E.F. Eriksen, P. Charles, T. Storm, L. Mosekilde.
The effects of high-dose glucocorticoid administration on serum bone gamma carboxyglutamic acid-containing protein, serum alkaline phosphatase and vitamin D metabolites in normal subjects.
Bone Miner, 4 (1988), pp. 105-113
[54.]
N.J. Ali, S. Capewell, M.J. Ward.
Bone turnover during high dose inhaled corticosteroid treatment.
Thorax, 46 (1991), pp. 160-164
[55.]
M. Muñoz Torres, P. Mezquita Raya, F. López Rodríguez.
Utilidad de los marcadores de remodelado óseo.
Endocrinología, 47 (2000), pp. 267-276
Copyright © 2003. Sociedad Española de Endocrinología y Nutrición
